Can-Fite BioPharma receives Australian Patent supporting Namodenoson development and marketing in liver and pancreatic cancer

Can-Fite BioPharma Ltd., a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced that the Australian

To access the full article, please log in or subscribe.